Immunosuppressive and corticosteroid therapy of polyarteritis nodosa

The American Journal of Medicine

Volumn 67, Issue 6, 1979, Pages 941-947

  Leib, Edward S ^a   Restivo, Carl ^a   Paulus, Harold E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; BUSULFAN; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

AUTOPSY; DRUG POTENTIATION; DRUG THERAPY; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR SYSTEM; POLYARTERITIS NODOSA; SURVIVAL; SURVIVAL RATE; THERAPY; VASCULAR DISEASE;

6-MERCAPTOPURINE; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AZATHIOPRINE; CORTISONE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGE; POLYARTERITIS NODOSA; PREDNISONE; PROGNOSIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0018607902     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(79)90634-X     Document Type: Article

References (42)

1. The natural history of polyarteritis
2. Polyarteritis nodosa
3. Long-term follow-up study of polyarteritis nodosa
4. The effect of cortisone on the lesions of periarteritis nodosa (abstract)
5. Treatment of polyarteritis nodosa with cortisone results after three years Report to the Medical Research Council by the collagen diseases and hypersensitivity panel
6. Immune complexes in hepatitis B antigen-associated periarteritis nodosa. Detection by antibody-dependent cell-mediated cytotoxicity and the Raji cell assay
7. Pneumocystis carinii associated with polyarteritis and immunosuppressive therapy
8. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa
9. Vasculitis with hepatitis B antigenemia. Long-term observations in nine patients
10. Long term immunosuppressive treatment of polyarteritis nodosa (abstract)
11. Quantiation and characterization of soluble immune complexes precipitated from sera by polyethylene glycol (PEG)
12. Biomedical computer programs P-series (BMDP-77)
13. Biomedical computer programs P-series (BMDP-77)
14. Biomedical computer programs P-series (BMDP-77)
15. Polyarthritis, polyarteritis and hepatitis B
16. Association of polyarteritis and Australia antigen (abstract)
17. Australia antigen and polyarteritis nodosa
18. Ueber eine bisher nicht beschriebene eigenthümniche arteriener krankung (periarteritis nodosa) die mit morbus birghtii und rapid fortschreitender allgemeiner, muskellähmung einhergeht
19. Pathogenesis (histogenesis and aetiologie) der aneurysmen einschliesslich des aneurysma equi verminosum
20. Ueber die sogenannte periarteriitis nodosa
21. Periarteritis nodosa: a critical review
22. The experimental demonstration that periarteritis nodosa is a manifestation of hypersensitivity
23. Studies on periarteritis nodosa III The differentiation between the vascular lesions of periarteritis nodosa and of hypersensitivity
24. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa
25. Cryoglobulinemia—a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity
26. Biologic and clinical significance of cryoglobulins A report of 86 cases
27. Mixed IgM-IgG cryoglobulinemia terminating in polyarteritis nodosa
28. Systemic “allergic” vasculitis. Clinical and pathological relationships
29. The necrotizing vasculitides A new pathogenetic classification
30. Chromosome translocation in association with periarteritis nodosa and macroglobulinemia
31. Association between polyarteritis and Australia antigen
32. Hepatitis associated antigen and periarteritis nodosa (PAN)
33. Immunologic mechanisms in systemic vasculitis
34. Polyarteritis nodosa. A distinct or an overlap vascuiitis (abstract)?
35. Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa
36. The relation of periarteritis nodosa to bronchial asthma and other forms of human hypersensitivities
37. Prognostic factors in polyarteritis
38. Periarteritis nodosa—a remission achieved with combined prednisone and azathioprine therapy
39. Systemic lupus erythematosus: a clinical analysis. Immunosuppressive therapy with cytotoxic drugs
40. Immunosuppressive and antiinflammatory properties of cyclophosphamide azathioprine and methotrexate
41. Immune complex disease in experimental animals and man